Focus: IGC Pharma is a public-stage pharmaceutical company headquartered in Potomac, MD, focused on cannabinoid-based therapeutics for neurology, particularly Alzheimer's disease. The company is early-stage with minimal revenue generation and operates as a clinical-stage biotech.
Profile data last refreshed 5m ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow IGC Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from IGC Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for IGC Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026 - Arizona Daily Sun
IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026 Arizona Daily Sun
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - StreetInsider
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout StreetInsider
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Newswire.com
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout Newswire.com
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 TradingKey
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 TradingKey
The 6 Best Stocks Under 50 Cents To Buy This Year - The Stock Dork
The 6 Best Stocks Under 50 Cents To Buy This Year The Stock Dork
Showing 6 of 10 news items
No open positions listed yet.
Recent peer-reviewed publications with author affiliations at this company
Factors linked to informal caregiver burden in dementia across Latin America and the Caribbean: A systematic review and meta-analysis.
The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo